S&P Futures
3,809.50 -17.75 (-0.46%) Dow Futures
30,929.00 -132.00 (-0.42%) Nasdaq Futures
11,543.75 -67.50 (-0.58%) Russell 2000 Futures
1,717.50 -11.00 (-0.64%) Crude Oil
108.31 -0.12 (-0.11%) Gold
1,803.30 +1.80 (+0.10%)
TG Therapeutics, Inc. (TGTX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 4.2500 |
| Open | 4.2300 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 800 |
| Day's Range | 4.2200 - 4.5800 |
| 52 Week Range | 3.4800 - 40.6600 |
| Volume | |
| Avg. Volume | 3,314,358 |
| Market Cap | 660.068M |
| Beta (5Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4580 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.88 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TGTX
Related Research
- TG Therapeutics, Inc.The Argus Dividend Growth Model PortfolioDividend income, an important element of total return, is often overlooked amid gyrations in the stock market. Between 1930 and 2012, dividend income accounted for 42% of the total return of the S&P 500, according to Hartford Funds. And that's just the average. In some decades, dividends accounted for more than 50% of total returns and even 100% of returns. More recently, dividends have accounted for 15%-20% of returns. Still, in 2018, dividend payments softened the blow when most market indices declined as the Federal Reserve hiked rates. The pattern is being repeated in 2022 as well. Not all dividends are created equal, though, and it is important to understand the difference between the two main categories: high-yield stocks and dividend-growth stocks.RatingFair ValueEconomic Moat7 days agoArgus Research
- GlobeNewswire
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 8th Congress of the European Academy of Neurology (EAN). Links to the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We a
- Zacks
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Simply Wall St.
TG Therapeutics (NASDAQ:TGTX) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
